Growing Innovation in Oncology – Spreading Hope for Autoimmune Disorders
Autoimmune disorders share immense burden of disease worldwide. Autoimmune disorders and hematologic malignancies are driven by the recruitment of immune cells (such as B cells, T cells, and NK cells) and overlapping biochemical pathways regulating immune cell functioning. There is a precedence of therapies approved for hematological malignancies, finding use in autoimmune indications as well.
SmartOncology Newsletter December 2020
Advances in the Development of HER3 Targeting Agents
COVID-19 and Cancer Care
The COVID-19 pandemic has impacted cancer patient care and clinical trial strategies. It has led to modified protocols, reprioritization of treatments and repositioning of cancer drugs for COVID treatment.
SmartOncology Newsletter, July 2020
Liquid biopsies – a revolution in multi-modal Dx testing?
Next Generation of Immune Checkpoint Therapy – Progress and Challenges of Immune-Modulatory Bispecifics
Next Generation of Immune Checkpoint Therapy – Progress and Challenges of Immune-Modulatory Bispecifics
